Thus, the use of HIF1α inhibitors should be evaluated with caution as it may increase the risk of obesity-induced inflammatory complications such as psoriasis and rheumatoid arthritis or risk of infections. This evidence concerns the gene HIF1A and rheumatoid arthritis.